CHLA researcher receives $3.7 million NIH grant to study development of neural circuits

Pat Levitt, PhD, Chief Scientific Officer at Children’s Hospital Los Angeles and Simms/Mann Chair in Developmental Neurogenetics, received a $3.7M grant from the National Institute of Mental Health to study development of neural circuits.

Our laboratory investigates how the wiring of the brain that underlies cognition and social and emotional behavior is built over time. We want to determine the genetic factors that interact with early experiences to influence how these brain circuits develop.”

Pat Levitt, PhD

Early brain development is driven largely by genetic information. But as circuits form, there are specific periods of time during which the forming connections are plastic: experience and environmental factors modify the brain’s synapses – the connections between neurons – and shape their maturation. Although neuroscientists know that these windows exist, the mechanisms that control when these critical periods occur are a mystery. A better understanding will lay the groundwork for studies that can use experience and other ingredients of development to promote healthy brain circuit formation and function.

Dr. Levitt’s team discovered that a gene for a protein called the MET receptor functions in the developing brain to control the timing of when specific synapses mature. The new funding will allow the research team to determine the brain cells that are dependent upon proper function of MET to form healthy connections. His team will use advanced genetic tools to manipulate MET timing in preclinical models and determine how windows of optimal plasticity for learning and other behaviors can be controlled during development.

Children’s Hospital Los Angeles

You Might Like

Articles You May Like

If you had Covid before you were vaccinated, you might have less immunity than you think, study says
Moderna CEO Stephane Bancel defends fivefold price hike of Covid vaccine during Senate grilling
Military Pilots, Ground Crew at Higher Risk of Cancer
Upgraded tumor model points the way toward more effective cancer therapies
US Officials Consider Second Bivalent Booster Despite First Dose’s Poor Reception: Report

Leave a Reply

Your email address will not be published. Required fields are marked *